One of the standouts of today's morning trading session has been BioNTech SE, which logged a -9.3% drop and underperformed the S&P 500 by -9.0%. The Biotechnology stock is now trading at $85.37 per share and is -31.87% below its average target price of $125.3. Analysts have set target prices ranging from $98.34 to 188.73 dollars per share, and have given the stock an average rating of buy.
The market seems to share this optimistic view, since BioNTech SE has a short interest of only 3.5% (this is the percentage of the share float that is being shorted). Each short position represents an investor's expectation that the price of the stock will decrease in the future.
When a stock is sold short, it means an investor has borrowed shares of the stock from their broker, and then sold them at the going market price. The investor hopes for the price to decline, so that they might buy those shares back at a lower price in the future. Once they do, they can return the borrowed shares to their broker, and keep the profit they made on the transaction.
A possible indicator of market sentiment on a stock (besides its share price, of course) is the portion of institutional investors that make up its shareholders. Institutions such as banks, hedge funds, and wealth managers deploy significant resources towards identifying good investments. If they are invested heavily in a given company's stock, it could mean it's a good investment. Or it could mean the company is being targeted by a takeover attempt.
For what it's worth, institutions own 18.4% of BioNTech SE's shares, which is an average amount. It means that many institutions are invested, but not to the extent that they would be in a stock such as Apple or Amazon, whose institutional ownership rates hover around 60%. Bear in mind that institutional ownership is just one piece of the puzzle in determining market sentiment, and you should not consider this factor alone in making an investment decision.
Overall, there is positive market sentiment towards BioNTech SE because of an analyst consensus of strong upside potential, a buy rating, an average amount of shares sold short, and a very small number of institutional investors. Investors should not base their decisions on market sentiment only, they should also be aware of a stock's fundamentals before committing.
At a glance, here are some essential statistics you may want to know about BNTX:
-
It has trailing 12 month earnings per share (EPS) of $12.26 per share
-
BioNTech SE has a trailing 12 month Price to Earnings (P/E) ratio of 7.0 while the S&P 500 average is 15.97
-
The company has a Price to Book (P/B) ratio of 1.02 in contrast to the S&P 500's average ratio of 2.95
-
BioNTech SE is a Health Care company, and the sector average P/E and P/B ratios are 30.21 and 4.08 respectively
